Last update March 29, 2023

N,N′-Bis(2,3-dihydroxypropyl)-5-[N-(2-hydroxyethyl)glycolamido]-2,4,6-tri-iodoisophthalamide

Compatible

Safe product and/or breastfeeding is the best option.

X-ray contrast medium with 47% Iodine.

At latest update no published data were found on excretion into breast milk.

The various Iodinated contrast media for imaging examinations (X-rays, CT scans) are considered compatible with breastfeeding since they are rapidly eliminated with little or no release of iodine, not metabolized and virtually not absorbed when taken by mouth. They are structurally very similar to each other and one of them is their data no or minimal excretion in milk.

Given the low lipid solubility of the iodinated contrast, less than 1% of the dose administered to the mother just passing milk. Due to their low oral bioavailability, intestinal absorption is less than 1% of the dose that he may take the infant. The maximum dose just getting the baby is less than 0.01% of the maternal dose, which represents less than 1% of the dose administered to a nursing practice that is a radiological contrast examination.

Most experts and radiology scientific societies agree that after a radiological iodinated contrast examination is not necessary to wait no time to nurse.


See below the information of this related product:

Alternatives

  • Amidotrizoate (Safe product and/or breastfeeding is the best option.)
  • Iohexol (Safe product and/or breastfeeding is the best option.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

N,N′-Bis(2,3-dihydroxypropyl)-5-[N-(2-hydroxyethyl)glycolamido]-2,4,6-tri-iodoisophthalamide is Ioversol in Chemical name.

Is written in other languages:

N,N′-Bis(2,3-dihydroxypropyl)-5-[N-(2-hydroxyethyl)glycolamido]-2,4,6-tri-iodoisophthalamide is also known as

Group

N,N′-Bis(2,3-dihydroxypropyl)-5-[N-(2-hydroxyethyl)glycolamido]-2,4,6-tri-iodoisophthalamide belongs to this group or family:

Tradenames

Main tradenames from several countries containing N,N′-Bis(2,3-dihydroxypropyl)-5-[N-(2-hydroxyethyl)glycolamido]-2,4,6-tri-iodoisophthalamide in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 0 %
Molecular weight 807 daltons
Protein Binding 9 - 13 %
VD 0.26 l/Kg
pKa 11.72 -
Tmax 0.1 hours
1.5 hours

References

  1. Mattsson S, Leide-Svegborn S, Andersson M. X-RAY AND MOLECULAR IMAGING DURING PREGNANCY AND BREASTFEEDING-WHEN SHOULD WE BE WORRIED? Radiat Prot Dosimetry. 2021 Oct 12;195(3-4):339-348. Abstract Full text (link to original source)
  2. Liebel F. IOversol. Drug Summary. 2017 Full text (in our servers)
  3. AEMPS. Ioversol. Ficha técnica. 2014 Full text (in our servers)

Total visits

452

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM